长效卡博特韦与利匹韦林肌注后脑脊液药代动力学及抗病毒活性
16例配对脑脊液与血浆样本显示两药脑脊液浓度均超过野生型HIV-1体外EC50,全部受试者血浆和脑脊液HIV-1 RNA均<50拷贝/mL。
要点
- 长效卡博特韦与利匹韦林肌注后脑脊液浓度超过野生型HIV-1体外EC50
- 每4周或每8周方案下16例受试者脑脊液HIV-1 RNA均<50拷贝/mL
- 脑脊液浓度仅为血浆的0.30%–1.32%,但足以实现脑脊液病毒学控制
核心结论
- 长效卡博特韦与利匹韦林双药方案可在脑脊液达到治疗浓度并实现有效病毒学控制。
研究设计与样本
- 受试者接受卡博特韦LA 400 mg+利匹韦林LA 600 mg每4周肌注(n=3)或卡博特韦LA 600 mg+利匹韦林LA 900 mg每8周肌注(n=15)。
- 16例受试者在注射后7(±3)天获得可评估的稳态配对脑脊液与血浆样本。
主要发现
- 每4周组与每8周组脑脊液卡博特韦中位总浓度分别为0.011 μg/mL和0.013 μg/mL,为配对血浆浓度的0.30%和0.34%。
- 每4周组与每8周组脑脊液利匹韦林中位总浓度分别为1.84 ng/mL和1.67 ng/mL,为配对血浆浓度的1.07%和1.32%。
- 卡博特韦与利匹韦林脑脊液总浓度均超过各自对野生型HIV-1的体外EC50(分别为0.10 ng/mL和0.27 ng/mL)。
- 16例受试者血浆和脑脊液HIV-1 RNA均<50拷贝/mL,其中15例脑脊液HIV-1 RNA<2拷贝/mL。
关键数值与推荐
- 脑脊液卡博特韦浓度超过野生型HIV-1体外EC50 0.10 ng/mL。
- 脑脊液利匹韦林浓度超过野生型HIV-1体外EC50 0.27 ng/mL。
- 16例受试者脑脊液HIV-1 RNA均<50拷贝/mL,15例<2拷贝/mL。
临床怎么用
- 提示长效卡博特韦与利匹韦林双药方案对中枢神经系统HIV复制具有抑制作用。
- 脑脊液浓度远低于血浆但超过EC50,临床解读脑脊液穿透性时需结合蛋白结合与EC50综合判断。
局限性
- 采样时间为注射后7(±3)天单一时点,未覆盖给药间期全程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-acting (LA) formulations of cabotegravir, an HIV integrase inhibitor, and rilpivirine, an NNRTI, are in development as monthly or 2 monthly intramuscular (IM) injections for maintenance of virological suppression. OBJECTIVES: To evaluate cabotegravir and rilpivirine CSF distribution and HIV-1 RNA suppression in plasma and CSF in HIV-infected adults participating in a substudy of the Phase 2b LATTE-2 study (NCT02120352). METHODS: Eighteen participants receiving cabotegravir LA 400 mg + rilpivirine LA 600 mg IM [every 4 weeks (Q4W), n = 3] or cabotegravir LA 600 mg + rilpivirine LA 900 mg IM [every 8 weeks (Q8W), n = 15] with plasma HIV-1 RNA <50 copies/mL enrolled. Paired steady-state CSF and plasma concentrations were evaluable in 16 participants obtained 7 (±3) days after an injection visit. HIV-1 RNA in CSF and plasma were assessed contemporaneously using commercial assays. RESULTS: Median total CSF concentrations in Q4W and Q8W groups, respectively, were 0.011 μg/mL and 0.013 μg/mL for cabotegravir (0.30% and 0.34% of the paired plasma concentrations) and 1.84 ng/mL and 1.67 ng/mL for rilpivirine (1.07% and 1.32% of paired plasma concentrations). Cabotegravir and rilpivirine total CSF concentrations exceeded their respective in vitro EC50 for WT HIV-1 (0.10 ng/mL and 0.27 ng/mL, respectively). All 16 participants had HIV-1 RNA <50 copies/mL in plasma and CSF, and 15 of 16 participants had HIV-1 RNA <2 copies/mL in CSF. CONCLUSIONS: A dual regimen of cabotegravir LA and rilpivirine LA achieved therapeutic concentrations in the CSF resulting in effective virological control in CSF.
引用
- Letendre SL, Mills A, Hagins D, et al. Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults. J Antimicrob Chemother. 2020. PMID: 31873746. doi:10.1093/jac/dkz504
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。